Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma Review


Authors: Silk, T.; Silk, M.; Wu, J.
Review Title: Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
Abstract: Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on “the up to seven” criteria and its utility in selecting systemic therapy. ©The Author(s) 2022.
Keywords: treatment response; overall survival; review; hepatocellular carcinoma; sorafenib; bevacizumab; chemoembolization; liver cell carcinoma; patient selection; systemic therapy; cancer patient; cancer staging; ticilimumab; cancer immunotherapy; progression free survival; tumor volume; practice guideline; immunotherapy; medical oncology; drug combinations; brivanib; nivolumab; regorafenib; lenvatinib; human; pembrolizumab; durvalumab; orantinib
Journal Title: World Journal of Gastroenterology
Volume: 28
Issue: 23
ISSN: 1007-9327
Publisher: Baishideng Publishing Group Inc  
Date Published: 2022-06-21
Start Page: 2561
End Page: 2568
Language: English
DOI: 10.3748/wjg.v28.i23.2561
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 August 2022 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Mikhail Thomas Silk
    15 Silk